Blackstone (NYSE:BX) Agreed A $1.5 Billion ZO Skin Health Exit

• Blackstone (NYSE:BX) agreed to sell ZO Skin Health to Galderma for US$1.5b in cash, as announced in October 2026.
• AirTrunk, backed by Blackstone, postponed its planned US$1.5b IPO to 2027, citing market volatility for the delay.
• Firmus Technologies may be required to repurchase shares from Blackstone and Nvidia if its IPO does not proceed as planned.
• Galderma's US$1.5b purchase of ZO Skin Health is only one example of how Blackstone is managing exits and IPO risk. Take a look at 3 warning signs (1 major) we have identified for Blackstone.

These moves around healthcare exits and delayed listings are closely related to how investors think about the wider buildout of digital infrastructure and data capacity, which brings a broader group of potential opportunities into view through 92 AI infrastructure stocks.

Blackstone uses its US$142.8b scale in alternative assets to buy, grow, and eventually exit holdings across private equity, credit, and real estate. Deals like ZO Skin Health and the IPO timing for AirTrunk feed directly into how it recycles capital across its broader platform.

3 things going right for Blackstone that this headline doesn't cover.

How does the ZO Skin Health sale fit into Blackstone’s broader plan?

The US$1.5b cash deal with Galderma shows Blackstone converting a healthcare holding into liquidity that can be recycled into new ideas. It lines up with the firm’s model of moving capital from mature assets into areas like AI infrastructure, data centers and new platforms, where it sees room to deploy its US$142.8b scale.

What do AirTrunk’s IPO delay and the Firmus buyback risk tell you about Blackstone’s approach to exits?

Pushing AirTrunk’s planned US$1.5b listing to 2027 and facing potential repurchases via Firmus highlight how Blackstone has to juggle timing, financing terms and partner agreements. Public markets are one route to realising value, but structured exits, trade buyers and private deals can all affect how quickly capital actually comes back.

What is the clearest thing to watch next for this Blackstone story?

The key marker is how much realised cash Blackstone reports from exits like ZO Skin Health compared with any outflows tied to arrangements such as the Firmus buyback over the next 12 to 18 months. A widening difference between sale proceeds and these obligations would indicate that the recycling engine is working more effectively for investors.

One piece of the Blackstone puzzle this article has not touched

Everything investors have read here still leaves one big question open, which is what Blackstone’s stream of incoming and outgoing cash suggests about the value implied by its current share price. Find out exactly what Blackstone is worth today based on its cash flows.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com